Background
aBsTraCT Background Iron deficiency (ID) is an emerging problem in patients with chronic heart failure (HF) and can be a potential therapeutic target. However, not much is known about the prevalence, predictors, and prognosis of ID in patients with chronic HF.
methods
In an international pooled cohort comprising 1506 patients with chronic HF, we studied the clinical associates of ID and its prognostic consequences.
results Iron deficiency (defined as a ferritin level < 100 μg/L or ferritin 100-299 μg/L with a transferrin saturation < 20%) was present in 753 patients (50%).
Anemic patients were more often iron deficient than non-anemic patients (61.2% vs 45.6%, P < 0.001). Other independent predictors of ID were higher New York Heart Association class, higher N-terminal pro-brain-type natriuretic peptide levels, lower mean corpuscular volume levels, and female sex (all P < 0.05). During follow-up (median 1.92 years, interquartile range 1.18-3.26 years), 440 patients died (29.2%). Kaplan-Meier survival analysis revealed ID as a strong predictor for mortality (log rank χ(2) 10.2, P = 0.001).
In multivariable hazard models, ID (but not anemia) remained a strong and independent predictor of mortality (hazard ratio 1.42, 95% confidence interval 1.14-1.77, P = 0.002). Finally, the presence of ID significantly enhanced risk classification and integrated discrimination improvement when added to a prediction model with established risk factors.
conclusions Iron deficiency is common in patients with chronic HF, relates to disease severity, and is a strong and independent predictor of outcome. In this study, ID appears to have greater predictive power than anemia. 
InTroduCTIon
Despite improvements in chronic heart failure (HF) treatment over the years, normal daily activities of many patients remain restricted.1 Anemia, a common comorbidity in HF, is associated with increased disease severity and may contribute to a worse outcome.2 -5 Thee mechanism through which anemia contributes to adverse outcome in chronic HF patients is complex and multifactorial.6 Important factors include renal failure, bone marrow resistance to erythropoietin, chronic inflammation, medication use and hematinic deficiencies, in particular iron deficiency (ID).7 -9 Traditionally, the presence of ID is only considered clinically relevant in the presence of anemia. However, a reduced hemoglobin levels can be viewed as the end result of a process beginning with gradual depletion of iron stores.10 , 11 Even if patients are not anemic, ID may already be common in chronic HF.12 , 13 Iron deficiency, with or without anemia, is associated with decreased aerobic performance and exercise intolerance,14 recently also shown in chronic HF.15
In recent years, a number of studies have shown that correction of ID 
Pooled methodology
The pooled data in the present study were assessed at a patient level. 
Iron status and other laboratory measurements
Peripheral venous blood samples were collected from all patients. Hematologic indices were assessed from fresh venous blood using EDTA.
After centrifugation, the remainder was frozen and stored before analysis.
Anemia was defined as a hemoglobin level < 12 g/dL in women and < 13 g/ dL in men. 29 The following blood biomarkers reflecting iron status were 
Statistical analyses
Data are expressed as means ± SD when normally distributed, as medi- calculate the predictive value of ID and anemia for all-cause mortality. The proportionality assumption for the Cox regression analysis was evaluated using Schoenfeld residuals and was proven to hold (χ2 18.04, P = 0.261).
In 2 consecutive multivariable models, both ID and anemia were adjusted for age, sex, eGFR, NT-proBNP levels, and finally for all significant univariable variables. Furthermore, we analysed the relationship between ID and mortality in patients with and without anemia.
Finally, risk stratification improvement of ID on top of established clinical risk factors was tested using net reclassification improvement and inte-grated discrimination improvement.31 Clinical risk factors included age, sex, diabetes, NYHA functional class, eGFR, levels of NT-proBNP and hs-CRP, and the presence of anemia. We used risk categories of < 5%, 5 -10%, 10 -20%, and > 20%. All tests were 2 sided, and a P value < 0.05 was considered statistically significant. All statistical analyses were performed using STATA version 11.0 (StataCorp LP, College Station, TX).
resulTs

Baseline characteristics
Baseline patient characteristics for all 1506 patients are shown in Table 1 .
Iron deficiency was present in 753 patients (50%). Anemia was present in 426 patients (28.3%). Patients with anemia were more often iron deficient compared to nonanemic patients (61.2% vs. 45.6%, respectively, P < 0.001).
Patients with both ID and anemia were older and had a higher NYHA class, more comorbidities, and higher biomarker levels compared with patients with ID and no anemia ( Supplementary Table 2 ). Stratification by NYHA functional class revealed that both anemia and ID increased with higher NYHA class ( Figure 1 ). Characteristics stratified per participating cohort were also described ( Supplementary Table 3 ).
Prevalence of iron deficiency and and/or stratified by NYHA functional class. 
clinical predictors of iron deficiency
The univariable logistic regression model is shown in Table 2 . When combined in a stepwise backward multivariable logistic regression model, only female sex, higher NYHA class, lower mean corpuscular volume, higher NT-proBNP levels and anemia remained independent predictors of ID in chronic HF patients. In additional bootstrap analysis, these 5 parameters remained highly selected. Moreover, there was no significant association between ID and treatment with antiplatelet drugs, anticoagulants, or other medication. Values are odds ratios ± 95% confidence intervals. Iron deficiency was defined as a ferritin level < 100 µg/L or 100-299 µg/L with a TSAT < 20%. *Anemia was defined as hemoglobin < 12 g/dL in women and < 13 g/dL in men. †MCV was measured in 596 non-iron deficient and 527 iron deficiency patients. ‡ hs-CRP was measured in 549 non-iron deficient and 451 iron deficient patients.
Iron deficiency and prognosis in chronic heart failure
During a mean follow-up of 2.52 ± 2.05 years (median 1.92 years, interquartile range 1.18 -3.26 years), 440 patients (29.2%) died. No significant association was observed between participating study cohort and outcome (P = 0.784). Similarly, no significant interaction was seen between ID or anemia and study cohort (P = 0.616 and 0.184, respectively). After 6 months of follow-up, mortality rates between people with and without ID already figure 2. Kaplan-Meier curves reflecting the difference in event-free survival rates in chronic heart failure patients with or without iron deficiency (ID) (A) and between iron deficient and non-iron deficient patients with or without anemia (B). differed significantly (8.7% vs. 3.6% respectively, P < 0.001). Differences remained statistically significant for the duration of follow-up. Differences in event-free 8-year survival between different patient groups are shown in Figure 2 . Increased mortality was observed in patients with ID versus without ID (P = 0.001). Similarly, increased mortality was observed in patients with both ID and anemia versus iron-deficient patients without anemia (P < 0.001).
In consecutive multivariable Cox regression models, ID -but not anemia -remained an independent predictor for mortality (hazard ratio [HR] 1.42, 95% CI 1.14 -1.77,P = 0.002), even after adjustment for all univariable associated variables ( Table 3 ). Multivariable hazard analyses of ID among specific clinical and comorbid subgroups of chronic HF patients are described in Figure 3 . Iron deficiency had more prognostic power in patients with more advanced HF (based on NYHA class) and had a trend toward worse outcome in men, younger patients, ischemic HF, HF with reduced ejection fraction, and patients with a decreased eGFR (b60 mL/min/1.73 m2). Finally, we investigated the predictive value of ID for mortality in patients with or without anemia (Figure 4 ). No significant interaction was observed between ID and anemia (P = 0.841). Iron deficiency remained an independent predictor of mortality in anemic (HR 1.71, 95% CI1.24 -2.36, P = 0.001) and nonanemic patients (HR 1.44, 95% CI 1.11 -1.87, P = 0.006).
additive prognostic value of iron deficiency
Deceased and alive patients were classified separately into low (< 5%), intermediate (5 -10%, 10 -20%), or high risk (> 20%) categories for mortality.
The net improvement in reclassification was estimated at 0.071 (P < 0.001) after the presence of ID was added to the prediction model. The integrated discrimination improvement was estimated at 0.008 (P = 0.003).
dIsCussIon
In a large international pooled cohort of diverse chronic HF patients, we demonstrated that ID is common, affecting half the study population.
Secondly, ID was closely related to disease severity, assessed using NYHA functional class and NT-proBNP levels. Thirdly, our findings demonstrate that ID identifies those with an enhanced risk for death, independently of other well-established predictors of outcome, including anemia. The pres- ent study also shows that the presence of ID adds significant prognostic information on top of established clinical risk factors.
Pathophysiology of Id in chronic HF
It was recently shown that patients with chronic HF are more susceptible to become iron deficient. This could be explained by gradual depletion of iron stores,(absolute ID) due to low iron intake, gastrointestinal blood loss, or iron malabsorption.32 Chronic inflammation, commonly observed in chronic HF, may also play a role. Inflammation causes reduced iron absorption and availability of iron recycled in the reticuloendothelial system (functional ID).33 -35 Therefore, functional ID may occur despite adequate iron stores, whereas iron stores are depleted in absolute ID.
Prevalence and definition of Id
In recent years, the prevalence and prognosis of ID in chronic HF have received greater attention. Despite this, there is no standard definition of ID in chronic HF, leading to a wide variation in reported prevalence. Opasich 13,15 -20,25,30 Using this definition, we demonstrated that the prevalence of ID in this large cohort was 50%.
There was also a significant difference in the prevalence of ID between anemic and nonanemic patients (61.2% vs. 45.6%, P < 0.001).
Predictors of iron deficiency
In the present study, several clinical characteristics were associated with ID. In this study, ID is a strong predictor for mortality, independently of other well-established outcome predictors including anemia. Even in nonanemic patients, ID still predicts outcome, whereas the presence of anemia in patients without ID does not. Over the years, anemia has been associated with an adverse outcome in patients with chronic HF. The mechanism by which anemia contributes to an adverse outcome in these patients is complex and multifactorial.6 It is unknown whether it is anemia that contributes to adverse prognosis or whether one of the factors contributing factors to anemia, such as inflammation, also contributes to adverse outcome.40 
Study limitations
ConClusIons
Iron deficiency is an emerging problem in chronic HF, affecting half of the patients. A decreased iron status is associated with disease severity (assessed by NYHA functional class and NT-proBNP levels), the presence of anemia and female sex. In this large international pooled cohort, ID is a strong and independent predictor of outcome. Finally, inclusion of ID provides additive prognostic value when added to a prediction model with established risk factors.
suPPlemenTal fIles 5. Able to understand the study procedures and willing to provide informed consent.
5.
Active and/or treated malignancies within 12 months before inclusion.
6. Clinically significant renal dysfunction or liver function abnormalities.
7. Severe anemia at baseline (hemoglobin < 10 g/dL).
8. Pregnancy or active breast-feeding (pregnancy tests will be performed on all female subjects of childbearing potential) 9. Use of any investigational drugs (within 30 d before screening). μg/L or 100 to 299 μg/L with a TSAT < 20%. †Anemia was defined as hemoglobin < 12 g/dL in women and < 13 g/dL in men. ‡Mean corpuscular volume was measured in 596 non-iron-deficient and 527 iron-deficient patients. §High-sensitive C-reactive protein was not measured in 549 non-iron-deficient and 451 iron-deficient patients. For abbreviations, see Table 1 . μg/L or 100 to 299 μg/L with a TSAT < 20%. † Mean corpuscular volume was measured in 596 non-iron-deficient and 527 iron-deficient patients. ‡High-sensitive C-reactive protein was not measured in 549 non-iron-deficient and 451 iron-deficient patients. For abbreviations, see Table 1 .
